By continuing to use this site, you consent to our use of cookies to personalize your experience and to analyze website traffic. Learn more in our Privacy Policy.

Accept
Privacy Policy

Discover updates to RELiZORB and what they may mean for you #

#

Get to know the redesigned RELiZORB cartridge

Discover a new look and expanded uses with all the same features that make RELiZORB easy to use and helpful for your tube-feeding needs

RELiZORB Cartridge

RELiZORB has an updated look, but it is still the only FDA-cleared enzyme product that breaks down fats in enteral formula

Not every tube-fed patient has the same approach to feeding. In order to better support your needs, RELiZORB has been redesigned for expanded utilization.

What's changed?

  • RELiZORB has an updated look for both the cartridge and packaging, which now feature bright-orange coloring
  • RELiZORB will have expanded utilization, including:
    • Compatibility with continuous and bolus feeding
    • Increased use of up to 6 cartridges per day
    • Expanded formula compatibility, allowing for use with some formulas with insoluble fibers*
  • In order to continue to offer you the most current resources, an updated product-use guide and additional materials are available on the Support & Resources page

What’s stayed the same?

  • RELiZORB is the only FDA-cleared enzyme product that breaks down fats in enteral formula
  • The new RELiZORB cartridge is ENFit® compatible and connects directly to enteral feeding tubes and supplies
  • For at-home use, patients should continue to order RELiZORB directly from their specialty pharmacy. For more information, contact RELiZORB Support Services at 1-844-632-9271 or email [email protected]

When will I receive the redesigned RELiZORB? 

If you’re currently using RELiZORB, you will receive the redesigned RELiZORB in the coming months. Look for the orange cap—RELiZORB will have a new look for both the product and packaging.

Continue to use RELiZORB as you always have, as directed by your healthcare provider.

If you have any questions, contact RELiZORB Support Services at 1-844-632-9271 or email [email protected].

*Please see list of compatible formulas and hydrolysis information.

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.

Warnings
  • RELiZORB is for use with enteral feeding only.
See more
#

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.

Warnings
  • RELiZORB is for use with enteral feeding only.
  • RELiZORB should not be connected to any intravenous (IV) line, setup, or system.
  • Medications should not be administered through the RELiZORB cartridge. Do not add medications to the enteral formula or tubing before RELiZORB. The passage of medications through RELiZORB may adversely affect the medications or the ability of RELiZORB to hydrolyze fats.
  • Fibrosing Colonopathy - Fibrosing colonopathy is a rare, serious adverse reaction associated with high-dose use of pancreatic enzyme replacement therapy in the treatment of patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. RELiZORB contains lipase enzyme that is not from a porcine source. The lipase is bound to the beads, and this lipase-bead complex (iLipase) is retained within the RELiZORB cartridge. Continue to follow your physician’s guidance and porcine pancreatic enzyme labeling regarding porcine pancreatic enzyme use when used in conjunction with RELiZORB.
Cautions and Precautions
  • Do not re-use RELiZORB. RELiZORB is a single-use product. Re-use may result in contamination of the product. If re-used, RELiZORB may not effectively hydrolyze fats.
  • Do not break, alter, or place excess pressure on any part of RELiZORB. Any compromise of the structural integrity of RELiZORB may lead to improper connection to enteral feeding supplies, enteral formula leakage or risk of contamination.
  • Do not use RELiZORB after the date marked on the pouch.
  • Do not use blenderized formulas with RELiZORB. A detailed listing of enteral formulas compatible with RELiZORB can be found at www.relizorb.com/compatibility.
  • RELiZORB is designed for use with enteral feeding pump systems with low flow/no flow alarms and enteral syringes for bolus syringe push. A detailed listing of formulas, pumps, and enteral feeding supplies compatible with RELiZORB can be found at www.relizorb.com/compatibility.
  • Do not use excessive force when using RELiZORB with enteral syringe push feeding methods.
  • Do not rush bolus feeds. Follow guidance from your healthcare professional on how long it should take you to complete your tube feeding.
  • Ensure all inlet and outlet connectors on RELiZORB and enteral feeding supplies are clean and dry prior to making connections.
  • In order to ensure product performance, store RELiZORB in its pouch either refrigerated or at room temperature (2°C to 27°C; 36°F to 80°F).
  • RELiZORB is indicated for use with enteral feeding only; patients should follow physician’s guidance for pancreatic enzyme replacement therapy (PERT) use for meals and snacks. Patients and patient caregivers should follow physician’s guidance regarding the need for pancreatic enzyme replacement therapy (PERT) during enteral feeding.

Review full product information for RELiZORB in the Instructions for Use.